Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones
Annexon, a biopharmaceutical company, announced positive Q4 and full-year 2025 financial results, highlighting significant progress in its immunotherapy programs for neuroinflammatory diseases. Key milestones include upcoming Phase 3 data for vonaprument in geographic atrophy, European MAA filing for tanruprubart in Guillain-Barré syndrome, and advancement of ANX1502 in autoimmune disease trials, aiming to address large underserved markets. The company’s approach targets the classical complement pathway to provide meaningful functional benefits for patients.